Page last updated: 2024-10-17

lactic acid and Coronary Restenosis

lactic acid has been researched along with Coronary Restenosis in 30 studies

Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.

Coronary Restenosis: Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.

Research Excerpts

ExcerptRelevanceReference
" The DESolve system, designed to provide vessel support and neointimal suppression, combines a poly-l-lactic acid-based scaffold with the antiproliferative myolimus."5.19A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. ( Abizaid, A; Abizaid, AS; Bhat, V; Chamie, D; Costa, JR; Costa, R; Morrison, L; Ormiston, JA; Pinto, I; Sanidas, E; Stewart, J; Toyloy, S; Verheye, S; Webster, M; Yan, J, 2014)
"PTCA-NC followed by local infusion of sirolimus nanoparticles was safe and efficacious to reduce neointima in this model, and this strategy may be a promising treatment for BMS ISR."3.79Local delivery of sirolimus nanoparticles for the treatment of in-stent restenosis. ( Attizzani, G; Balvedi, JA; Centeno, PR; Kosachenco, BG; Matte, BS; Nascimento, L; Raudales, JC; Yamamoto, GI; Zago, AC; Zago, AJ, 2013)
" The primary endpoint was a composite of major adverse cardiac events (MACE) at 180+/-14 days and expected to be below 20%."2.74The ProLimus trial: a prospective, non-randomised, multicentre trial to evaluate the safety and clinical performance of the pimecrolimus eluting stent system (ProGenic). ( Agostoni, P; Birkemeyer, R; Grube, E; Haine, S; Haude, M; Jung, W; Müller, R; Sarno, G; van Langenhove, G; Verheye, S; Vrints, C; Wijns, W; Willems, T, 2009)
"Montelukast (MK) is a selective cysLT1 receptor antagonist, with anti-inflammatory and anti-proliferative properties, which has been used for treatment of various diseases."1.43Electrosprayed Montelukast/poly (lactic-co-glycolic acid) particle based coating: A new therapeutic approach towards the prevention of in-stent restenosis. ( Mhaisalkar, PS; Prabhakaran, MP; Ramakrishna, S; Varshosaz, J; Zamani, M, 2016)

Research

Studies (30)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's15 (50.00)29.6817
2010's15 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Vergnol, G1
Renard, E1
Haroun, F1
Guerin, P1
Seron, A1
Bureau, C1
Loirand, G1
Langlois, V1
Oh, B1
Lee, CH1
Verheye, S2
Ormiston, JA1
Stewart, J1
Webster, M1
Sanidas, E1
Costa, R1
Costa, JR1
Chamie, D1
Abizaid, AS1
Pinto, I1
Morrison, L1
Toyloy, S1
Bhat, V1
Yan, J1
Abizaid, A1
Palumbo, FS1
Rigogliuso, S1
Ghersi, G1
Pitarresi, G1
Fiorica, C1
Calogero, F1
Di Stefano, M1
Giammona, G1
Xiao, J1
Feng, G1
Kang, G1
Lan, Z1
Liao, T1
Kislauskis, E1
Chen, J1
Xia, J1
Wang, Z2
Huo, Z1
Wang, Q1
Xi, T1
McCarthy, S2
Jiang, X1
Wu, T2
Laham, R2
Vannozzi, L1
Ricotti, L1
Filippeschi, C1
Sartini, S1
Coviello, V1
Piazza, V1
Pingue, P1
La Motta, C1
Dario, P1
Menciassi, A1
Zamani, M1
Prabhakaran, MP1
Varshosaz, J2
Mhaisalkar, PS1
Ramakrishna, S1
Han, Y1
Jing, Q1
Chen, X1
Wang, S1
Ma, Y1
Liu, H1
Luan, B1
Wang, G2
Li, Y1
Wang, D1
Xu, B1
Gao, R1
Ren, L2
Wang, J4
Tang, J2
Pan, C2
Huang, N4
Soheili, M1
Nakano, K1
Egashira, K2
Masuda, S1
Funakoshi, K2
Zhao, G1
Kimura, S1
Matoba, T1
Sueishi, K1
Endo, Y1
Kawashima, Y1
Hara, K1
Tsujimoto, H1
Tominaga, R1
Sunagawa, K1
Sarno, G1
Müller, R1
Birkemeyer, R1
Vrints, C1
Jung, W1
Agostoni, P1
van Langenhove, G1
Haine, S1
Willems, T1
Haude, M1
Grube, E3
Wijns, W2
Zou, W1
Cao, G1
Xi, Y1
Zhang, N1
Rodriguez, AE1
Vigo, CF1
Delacasa, A1
Mieres, J1
Fernandez-Pereira, C1
Bernardi, V1
Bettinoti, M1
Rodriguez-Granillo, AM1
Rodriguez-Granillo, G1
Santaera, O1
Curotto, V1
Rubilar, B1
Tronge, J1
Palacios, IF1
Antoniucci, D1
Danzi, GB1
Chevalier, B1
Ostojic, M1
Hamilos, M1
Ma, X1
Oyamada, S1
Gao, F1
Robich, MP1
Wu, H1
Wang, X1
Buchholz, B1
Gu, Z1
Bianchi, CF1
Sellke, FW1
Indolfi, L1
Causa, F1
Giovino, C1
Ungaro, F1
Quaglia, F1
Netti, PA1
Kadota, K1
Muramatsu, T1
Iwabuchi, M1
Saito, S1
Hayashi, Y1
Ikari, Y1
Nanto, S1
Fujii, K1
Inoue, N1
Namiki, A1
Kimura, T1
Mitsudo, K1
Koppara, T1
Joner, M1
Bayer, G1
Steigerwald, K1
Diener, T1
Wittchow, E1
Zago, AC1
Raudales, JC1
Attizzani, G1
Matte, BS1
Yamamoto, GI1
Balvedi, JA1
Nascimento, L1
Kosachenco, BG1
Centeno, PR1
Zago, AJ1
Sonoda, S1
Ikeno, F1
Honda, Y1
Kar, S1
Chan, C1
Gerckens, U1
Lansky, AJ1
Fitzgerald, PJ1
Yin, T1
Bhargava, B1
Reddy, NK1
Karthikeyan, G1
Raju, R1
Mishra, S1
Singh, S1
Waksman, R1
Virmani, R1
Somaraju, B1
Zweers, ML1
Engbers, GH1
Grijpma, DW1
Feijen, J1
Buellesfeld, L1
Pan, CJ2
Shao, ZY2
Tang, JJ2

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Percutaneous Coronary Intervention With the ANgiolite Drug-Eluting Stent: an Optical CoHerence TOmogRaphy Study. The ANCHOR Study[NCT02776267]100 participants (Anticipated)Interventional2015-05-31Completed
Multicenter, Randomized, Non-inferiority Study of Firebird 2 Versus Excel Sirolimus-eluting Stent in Treating Real-world Patients With Coronary Artery Disease[NCT01373632]Phase 4570 participants (Anticipated)Interventional2011-06-30Recruiting
Comparison Among a Paclitaxel Eluting Stent With Biodegradable Polymer Versus an Uncoated Bare Metal Stent. A Prospective, Multicentric and Randomized Study.(EUCATAX Trial)[NCT00825279]Phase 4300 participants (Actual)Interventional2007-08-31Completed
Percutaneous Complete Revascularization Strategies Using Sirolimus Eluting Biodegradable Polymer Coated Stents in Patients Presenting With Acute Coronary Syndrome and Multivessel Disease[NCT03621501]1,525 participants (Actual)Interventional2018-06-22Active, not recruiting
Vessel Injury in Relation With Strut Thickness Assessed by OCT (VISTA): A Comparison of Vascular Injury Induced by a Polymer Free Sirolimus and Probucol Eluting Stent and a Biodegradable-polymer Biolimus-eluting Stent[NCT03026465]Phase 450 participants (Actual)Interventional2017-02-16Completed
Prospective, Randomized Trial of 3 Rapamycin-Eluting Stents With Different Polymer Coating Strategies For The Reduction of Coronary Restenosis (ISAR-TEST-3)[NCT00350454]Phase 4605 participants (Actual)Interventional2006-06-30Completed
Clinical and Angiographic Evaluation of Paclitaxel Eluting, Non-Polymeric, Nanoporous Carbon-Carbon Coated, Cobalt-Chromium Stent[NCT00428662]200 participants Interventional2007-01-31Recruiting
A Randomized Optical Coherence Tomography Study Comparing Resolute Integrity to Biomatrix Drug-eluting Stent on the Degree of Early Stent Healing and Late Lumen Loss.The OCT-ORION Study[NCT01742507]Phase 460 participants (Actual)Interventional2012-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

4 reviews available for lactic acid and Coronary Restenosis

ArticleYear
Nobori™ drug eluting stent system: clinical evidence update.
    Minerva cardioangiologica, 2010, Volume: 58, Issue:5

    Topics: Clinical Trials as Topic; Coronary Restenosis; Drug-Eluting Stents; Equipment Design; Follow-Up Stud

2010
[Research progress of the drug-coated stents].
    Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi, 2005, Volume: 22, Issue:2

    Topics: Angioplasty, Balloon, Coronary; Coated Materials, Biocompatible; Coronary Restenosis; Drug Delivery

2005
BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease.
    Expert review of medical devices, 2006, Volume: 3, Issue:6

    Topics: Animals; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Restenosis; Drug Carrier

2006
[Molecular mechanism of in-stent restenosis and novel treatment strategy of gene-eluting stent developed with bioabsorbable nanoparticle electrodeposition].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2007, Volume: 129, Issue:3

    Topics: Absorbable Implants; Animals; Chemokine CCL2; Coronary Restenosis; Electrodes; Gene Transfer Techniq

2007

Trials

5 trials available for lactic acid and Coronary Restenosis

ArticleYear
A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results.
    JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:1

    Topics: Absorbable Implants; Aged; Aged, 80 and over; Belgium; Cardiovascular Agents; Coronary Angiography;

2014
The ProLimus trial: a prospective, non-randomised, multicentre trial to evaluate the safety and clinical performance of the pimecrolimus eluting stent system (ProGenic).
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2009, Volume: 5, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Belgium; Cardiovascular Agents; Chromium Alloys; Coronary Angi

2009
Efficacy and safety of a double-coated paclitaxel-eluting coronary stent: the EUCATAX trial.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2011, Feb-15, Volume: 77, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Argentina; Cardiovascular Agents; Chi-Square Distribution; Coa

2011
Randomized comparison of the Nobori biolimus A9-eluting stent with the sirolimus-eluting stent in patients with stenosis in native coronary arteries.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2012, Nov-01, Volume: 80, Issue:5

    Topics: Aged; Cardiovascular Agents; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Coronary

2012
Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer.
    Circulation, 2004, May-11, Volume: 109, Issue:18

    Topics: Aged; Anticoagulants; Catheterization; Cineangiography; Coated Materials, Biocompatible; Comorbidity

2004

Other Studies

21 other studies available for lactic acid and Coronary Restenosis

ArticleYear
Electrografting of a biodegradable layer as a primer adhesion coating onto a metallic stent: in vitro and in vivo evaluations.
    Journal of materials science. Materials in medicine, 2013, Volume: 24, Issue:12

    Topics: Angioplasty; Animals; Arteries; Biocompatible Materials; Cell Adhesion; Coronary Restenosis; Drug De

2013
Advanced cardiovascular stent coated with nanofiber.
    Molecular pharmaceutics, 2013, Dec-02, Volume: 10, Issue:12

    Topics: Cell Proliferation; Cells, Cultured; Chemistry, Pharmaceutical; Chitosan; Coronary Restenosis; Drug

2013
Dexamethasone dipropionate loaded nanoparticles of α-elastin-g-PLGA for potential treatment of restenosis.
    Molecular pharmaceutics, 2013, Dec-02, Volume: 10, Issue:12

    Topics: Animals; Cattle; Cell Differentiation; Cell Proliferation; Cells, Cultured; Coronary Restenosis; Dex

2013
6-Month Follow-Up of a Novel Biodegradable Drug-Eluting Stent Composed of Poly-L-Lactic Acid and Amorphous Calcium Phosphate Nanoparticles in Porcine Coronary Artery.
    Journal of biomedical nanotechnology, 2015, Volume: 11, Issue:10

    Topics: Absorbable Implants; Animals; Calcium Phosphates; Coronary Restenosis; Coronary Vessels; Drug Implan

2015
Nanostructured ultra-thin patches for ultrasound-modulated delivery of anti-restenotic drug.
    International journal of nanomedicine, 2016, Volume: 11

    Topics: Barium Compounds; Cardiovascular Agents; Cell Adhesion; Cells, Cultured; Coronary Restenosis; Drug C

2016
Electrosprayed Montelukast/poly (lactic-co-glycolic acid) particle based coating: A new therapeutic approach towards the prevention of in-stent restenosis.
    Acta biomaterialia, 2016, 09-15, Volume: 42

    Topics: Acetates; Calorimetry, Differential Scanning; Cell Count; Cell Movement; Cell Proliferation; Coated

2016
Long-term clinical, angiographic, and intravascular ultrasound outcomes of biodegradable polymer-coated sirolimus-eluting stents.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2008, Aug-01, Volume: 72, Issue:2

    Topics: Absorption; Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Coated Materials, Bioc

2008
[Influence of curcumin--loaded poly (lactide-co-glycolide) films on the proliferation of vascular smooth muscle cells].
    Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi, 2008, Volume: 25, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Animals; Carotid Arteries; Cell Proliferation; Cells, Cultured; Coat

2008
Production and in vitro characterization of lisinopril-loaded nanoparticles for the treatment of restenosis in stented coronary arteries.
    Journal of microencapsulation, 2008, Volume: 25, Issue:7

    Topics: Absorbable Implants; Cardiotonic Agents; Coronary Restenosis; Coronary Vessels; Humans; Lactic Acid;

2008
Formulation of nanoparticle-eluting stents by a cationic electrodeposition coating technology: efficient nano-drug delivery via bioabsorbable polymeric nanoparticle-eluting stents in porcine coronary arteries.
    JACC. Cardiovascular interventions, 2009, Volume: 2, Issue:4

    Topics: Absorbable Implants; Angioplasty, Balloon, Coronary; Animals; Cardiovascular Agents; Cations; Cells,

2009
New approach for local delivery of rapamycin by bioadhesive PLGA-carbopol nanoparticles.
    Drug delivery, 2009, Volume: 16, Issue:1

    Topics: Acrylic Resins; Adhesiveness; Animals; Cell Survival; Coronary Restenosis; Dogs; Drug Carriers; Drug

2009
Paclitaxel/sirolimus combination coated drug-eluting stent: in vitro and in vivo drug release studies.
    Journal of pharmaceutical and biomedical analysis, 2011, Mar-25, Volume: 54, Issue:4

    Topics: Animals; Antineoplastic Agents; Aorta, Abdominal; Calcium Phosphates; Coronary Artery Disease; Coron

2011
Nanoburrs seek, heal injury in artery.
    Harvard heart letter : from Harvard Medical School, 2011, Volume: 21, Issue:5

    Topics: Absorbable Implants; Atherosclerosis; Cardiotonic Agents; Coronary Restenosis; Coronary Vessels; Dru

2011
Microsphere-integrated drug-eluting stents: PLGA microsphere integration in hydrogel coating for local and prolonged delivery of hydrophilic antirestenosis agents.
    Journal of biomedical materials research. Part A, 2011, Volume: 97, Issue:2

    Topics: Animals; Chemistry, Pharmaceutical; Coronary Restenosis; Dextrans; Drug Delivery Systems; Drug-Eluti

2011
Histopathological comparison of biodegradable polymer and permanent polymer based sirolimus eluting stents in a porcine model of coronary stent implantation.
    Thrombosis and haemostasis, 2012, Volume: 107, Issue:6

    Topics: Absorbable Implants; Angioplasty, Balloon, Coronary; Animals; Cardiovascular Agents; Coronary Angiog

2012
Histopathological comparison of biodegradable polymer and permanent polymer based sirolimus eluting stents in a porcine model of coronary stent implantation.
    Thrombosis and haemostasis, 2012, Volume: 107, Issue:6

    Topics: Absorbable Implants; Angioplasty, Balloon, Coronary; Animals; Cardiovascular Agents; Coronary Angiog

2012
Histopathological comparison of biodegradable polymer and permanent polymer based sirolimus eluting stents in a porcine model of coronary stent implantation.
    Thrombosis and haemostasis, 2012, Volume: 107, Issue:6

    Topics: Absorbable Implants; Angioplasty, Balloon, Coronary; Animals; Cardiovascular Agents; Coronary Angiog

2012
Histopathological comparison of biodegradable polymer and permanent polymer based sirolimus eluting stents in a porcine model of coronary stent implantation.
    Thrombosis and haemostasis, 2012, Volume: 107, Issue:6

    Topics: Absorbable Implants; Angioplasty, Balloon, Coronary; Animals; Cardiovascular Agents; Coronary Angiog

2012
Local delivery of sirolimus nanoparticles for the treatment of in-stent restenosis.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2013, Volume: 81, Issue:2

    Topics: Acrylic Resins; Animals; Cardiac Catheters; Cardiovascular Agents; Chemistry, Pharmaceutical; Corona

2013
A novel paclitaxel-eluting porous carbon-carbon nanoparticle coated, nonpolymeric cobalt-chromium stent: evaluation in a porcine model.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2006, Volume: 67, Issue:5

    Topics: Analysis of Variance; Animals; Carbon; Chromium; Coated Materials, Biocompatible; Cobalt; Coronary A

2006
Release of anti-restenosis drugs from poly(ethylene oxide)-poly(DL-lactic-co-glycolic acid) nanoparticles.
    Journal of controlled release : official journal of the Controlled Release Society, 2006, Sep-12, Volume: 114, Issue:3

    Topics: Coronary Restenosis; Dexamethasone; Diffusion; Drug Carriers; Epoxy Compounds; Ethylene Oxide; Lacti

2006
In vitro studies of platelet adhesion, activation, and protein adsorption on curcumin-eluting biodegradable stent materials.
    Journal of biomedical materials research. Part A, 2007, Sep-01, Volume: 82, Issue:3

    Topics: Adsorption; Biocompatible Materials; Coated Materials, Biocompatible; Coronary Restenosis; Coronary

2007
Improved blood compatibility of rapamycin-eluting stent by incorporating curcumin.
    Colloids and surfaces. B, Biointerfaces, 2007, Sep-01, Volume: 59, Issue:1

    Topics: Absorbable Implants; Adsorption; Angioplasty, Balloon, Coronary; Blood; Coated Materials, Biocompati

2007
[Preparation and anticoagulation of curcumin/poly(lactic acid-co-glycol acid) composite films].
    Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi, 2008, Volume: 25, Issue:1

    Topics: Coated Materials, Biocompatible; Coronary Restenosis; Curcumin; Drug-Eluting Stents; Humans; Lactic

2008